Phosphagenix raises $4m in UK placement
03 November, 2004 by Melissa TrudingerPhosphagenics (ASX:POH) has raised £1.75 million (AUD$4.3 million) through a placement of about 18 million shares in the UK.
Pharmaxis raises $16.5m in placement
03 November, 2004 by Melissa TrudingerPharmaxis (ASX:PXS) has raised AUD$16.5 million in an oversubscribed placement to institutional and sophisticated investors in Australia.
Amrad, Ludwig beef up agreement
03 November, 2004 by Melissa TrudingerAmrad (ASX:AML) and the Ludwig Institute for Cancer Research have strengthened their collaboration for the development of vascular endothelial growth factor B (VEGF-B), which has potential applications in cancer and cardiovascular disease.
Pharmaxis to raise further funds
02 November, 2004 by Renate KrelleFollowing its recent announcement of a successful Phase III trial of the successful completion of a Phase III clinical trial for its asthma diagnostic and treatment management tool Aridol, Sydney's Pharmaxis (ASX:PXS) has entered a trading halt -- to be lifted tomorrow morning -- pending the announcement of details of a placement and share purchase plan.
Portland boss shares business secrets
02 November, 2004 by Renate KrellePortland Orthopaedics CEO David Sekel told a recent gathering of the Australian Venture Capitalists Association that the company's rush to prepare for an IPO last year -- a process which did not come to fruition -- had been premature, and that a trade sale was now an attractive option.
Tamiflu effective against H5N1 avian virus
02 November, 2004 by Staff WritersResearchers from the Queen Mary Hospital in London have said the Roche's neuraminidase inhibitor Tamiflu (oseltamivir) is effective against avian and human forms of the virus, which has so far killed 32 people this year.
NarHex IPO to fund Chinese HIV project
01 November, 2004 by Graeme O'NeillFacing a human and economic catastrophe, and with the Beijing Olympics less than four years away, the Chinese government has struck a unique deal with a small, Sydney-based company, NarHex Life Sciences, to fast-track clinical trials of one of the world's most promising new AIDS drugs.
Cryptome AGM sheds little light on CEO departure
01 November, 2004 by Renate KrelleCryptome (ASX:CRP) chairman Graham Kelly offered shareholders few clues about reasons behind the resignation of CEO Jeffrey Travis at today's annual general meeting, but the company has announced the appointment of Prof Mathew Vardas as acting CEO.
Benitec snaps up sixth licence, aims for $5m per year
29 October, 2004 by Graeme O'NeillBrisbane RNAi gene therapy company Benitec (ASX:BLT) has granted a global, non-exclusive licence for its gene-silencing technology to a German company that develops genetically modified mice for research.
Biota banks $20m, heads back to court
29 October, 2004 by Melissa TrudingerBiota (ASX: BTA) shareholders have shown resounding support for the company in an oversubscribed share purchase plan that has raised AUD$20 million.
License to grow says US CEO
29 October, 2004 by Melissa TrudingerIn-licensing of clinical-stage compounds for development is a useful way to build sustainable value for your company and fill out your pipeline, the CEO of San Diego company Structural Genomix (SGX) Timothy Harris told venture capitalists and other attendees at this week's AVCAL networking lunch in Melbourne.
NSW govt tipped to soften GM crop ban
28 October, 2004 by Graeme O'NeillIs the NSW Carr government -- the first state government to legislate for a moratorium on genetically modified crops -- having second thoughts?
Sirtex wins $1.3m Start grant
28 October, 2004 by Melissa TrudingerSirtex (ASX: SRX) has been awarded a AUD$1.311 million R&D Start grant from AusIndustry to commercialise its Targeted Hyperthermia Therapy.
Bush, Kerry both seen pressed to curb drug prices
27 October, 2004 by Staff WritersThe pharmaceutical industry is expected to face pressure to curb rising prescription-drug costs no matter which candidate wins next week's US presidential election.
NZ Roadshow: Why agbiotech must break free
27 October, 2004 by Graeme O'NeillIt's the Tasman paradox: although Australia and New Zealand are the world's leading exporters of grazing-derived products, they have both struggled to develop viable agricultural biotechnology industries. Why?
